Figure 1. Two months after initiating pemigatinib. Computed tomography scan showing the primary tumor in the intrahepatic region, lung, and bone metastases before pemigatinib treatment (A, B, C). Two months after initiating pemigatinib (C, D, E), All lesions were determined to be stable disease (RECIST version1.1) with a reduced length diameter within 20%. Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors.